Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CPPtat-S1 peptide is a cell-penetrating competitive peptide designed to inhibit the S-palmitoylation of Cluster of Differentiation 38 (CD38) at Cys16. This peptide functions by interfering with the interaction between CD38 and the palmitoyl transferase ZDHHC9, which is crucial for maintaining CD38 protein expression in tumor cells. By blocking this interaction, CPPtat-S1 peptide leads to a dose-dependent decrease in CD38 protein levels without affecting its transcriptional activity. This mechanism ultimately suppresses tumor progression, as demonstrated in preclinical pancreatic cancer models. The peptide is fused with a cell-penetrating peptide (CPPtat) to enhance its intracellular delivery.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CPPtat-S1 peptide.